Trials / Recruiting
RecruitingNCT06886126
Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus
Phase II Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Obese Nondiabetic Adult Subjects
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of HDM1005 injection in nondiabetic obese adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HDM1005 injection or placebo | HDM1005 injection subcutaneous injection QW for 22weeks |
Timeline
- Start date
- 2025-02-07
- Primary completion
- 2025-09-23
- Completion
- 2025-11-30
- First posted
- 2025-03-20
- Last updated
- 2025-09-30
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06886126. Inclusion in this directory is not an endorsement.